Tvardi Therapeutics Inc
Company Profile
Business description
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Contact
3 Sugar Creek Center boulevard
Suite 525
Sugar LandTX77478
USAT: +1 713 489-8654
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
12
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,956.20 | 5.20 | 0.06% |
| CAC 40 | 8,123.41 | 31.50 | -0.39% |
| DAX 40 | 25,410.63 | 168.22 | -0.66% |
| Dow JONES (US) | 51,511.59 | 352.10 | -0.68% |
| FTSE 100 | 10,705.26 | 3.07 | -0.03% |
| HKSE | 24,834.12 | 253.63 | -1.01% |
| NASDAQ | 26,936.04 | 308.24 | -1.13% |
| Nikkei 225 | 65,018.95 | 882.70 | 1.38% |
| NZX 50 Index | 13,821.76 | 53.72 | -0.39% |
| S&P 500 | 7,706.03 | 58.61 | -0.75% |
| S&P/ASX 200 | 8,765.30 | 7.50 | 0.09% |
| SSE Composite Index | 3,936.52 | 15.61 | -0.39% |